公开(公告)号：US20160159905A1

公开(公告)日：2016-06-09

申请号：US14958053

申请日：2015-12-03

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia ABDICHE ,  Helen Kim CHO ,  Weihsien HO ,  Karen Ute JOOSS ,  Arvind RAJPAL ,  Sawsan YOUSSEF

IPC: C07K16/28 ,  A61K39/39 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06

CPC classification number: A61K39/39 ,  A61K39/0011 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/53 ,  A61K2039/545 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Abstract translation: 本发明提供了结合程序性细胞死亡蛋白1（PD-1）的拮抗性抗体及其使用方法。 抗PD-1抗体可以治疗性地单独使用或与其它治疗剂组合用于治疗癌症和其它疾病。

公开(公告)号：US20160096898A1

公开(公告)日：2016-04-07

申请号：US14864750

申请日：2015-09-24

Applicant: RINAT NEUROSCIENCE CORP. ,  Pfizer Inc.

Inventor： Hong LIANG ,  Yasmina Noubia ABDICHE ,  Javier Fernando CHAPARRO RIGGERS ,  Bruce Charles GOMES ,  Julie Jia Li HAWKINS ,  Jaume PONS ,  Xiayang QIU ,  Pavel STROP ,  Yuli WANG

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Abstract translation: 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。

公开(公告)号：US20130273069A1

公开(公告)日：2013-10-17

申请号：US13857063

申请日：2013-04-04

Applicant: Pfizer Inc. ,  Rinat Neuroscience Corp.

Inventor： Hong LIANG ,  Yasmina Noubia ABDICHE ,  Javier Fernando CHAPARRO RIGGERS ,  Bruce Charles GOMES ,  Julie Jia Li HAWKINS ,  Jaume PONS ,  Xiayang QIU ,  Pavel STROP ,  Yuli WANG

IPC: C07K16/40 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Abstract translation: 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。